Effect of Thiazolidinediones (Glitazones) groups on Glycemic control and Lipid profile: A Meta-analysis of Randomized Control Trials
Meta-analysis of Randomized control trials of Thiazolidinediones
Keywords:
Diabetes mellitus, Glycemic control, Lipid profile, ThiazolidinedionesAbstract
Background & objectives: In patients with type 2 diabetes mellitus, all therapeutic options should be evaluated for their effect on cardiovascular risk factors, in addition to glycemic control. Randomized controlled trials of pioglitazone and rosiglitazone in patients with type 2 diabetes to evaluate their effect on either glycemic control or serum lipid profile individually have been reviewed and analyzed but analysis of reports of effect on both these parameters simultaneously are very few and such meta-analysis has not been carried out earlier. This article presents meta-analysis of randomized controlled trials of pioglitazone and rosiglitazone in patients with type 2 diabetes to evaluate their effect on glycemic control as well as serum lipid profile. Methods: We identified the citations by searching the web site of MD-consult, National Library of Medicine and Google for identifying randomized controlled trails pertinent to the thiazolidinediones of interest (rosiglitazone and pioglitazone) and evaluated then compared effect of these two drugs on glycemic control and serum lipid profile by applying student’s t-test.Results: Twelve randomized controlled trials (n=10052) were identified. Both thiazolidinediones produced significant reduction in HbA1c and FPG. Pioglitazone significantly reduced TG and increased HDL-C levels without significant effect on LDL-C and Total CH; while rosiglitazone significantly increased HDL-C, LDL-C, Total CH and slightly increased TG. Comparatively, they did not differ in their effect on glycemic control but regarding lipid profile, pioglitazone significantly reduced TG whereas rosiglitazone slightly increased TG level. Rosiglitazone produced significantly more increase in LDL-C and total CH level as compared to pioglitazone. Interpretation & conclusion: Pioglitazone had significantly more beneficial effects on lipid profile than Rosiglitazones and is clinically superior in patient of Type-2 DM with dyslipidemia.
References
2. Power AC, D’alessio D. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: Bruntun LL, Chabner BA, Knollrrann BC editors. Goodman & Gillman’s the pharmacological basis of therapeutics. 12th ed. McGraw Hill; 2011. P. 1237-1273.
3. Statistics calculaters (version 2.0) [online]. Available from: http://www.danielsoper.com/statcalc/c9/co8.ajpx. Accessed 2011, March 15.
4. Spanheims R, Betteridge DJ, Tan MH, et al. long term lipid effects of pioglitazone by baseline antihyperglycemia medication therapy and statin use from the PROacive experience (PROactive 14). The American journal of cardiology [serial online] 2009 july: 104(2). Available from: http://www.mdconsult.com/das/article/body/237643931-4/jorg. Accessed 2011, February 22.
5. Goldberg RB, Kendall DM, Deeg MA. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patient with type 2 diabetes and dyslipidemia. Diabetes care [serial online] 2005:28(No.7): 1547-1554. Available from: http://care.diabetesjournals.org/content/28/7/1547.full. Accessed 2011, February 22.
6. Aronoff S, Rosenblath S, Braithwaite S, et al. pioglitazone hydrochloride monotherapy omproves glycemic control in the treatment of patients with type 2 diabetes. Diabetes care [serial online] 2000:23:1605-1611. Available from: http://care.diabetesjournals.org/content/23/11/1605.full. Accessed 2011, February 22.
7. Kipnes MS, Krosnick A, Rendell MS, et al. pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. The American journal of medicine [serial online] 2001 July: 111(1). Available from: http://www.mdconsult.com/das/article/body/237779776-4/jorg. Accessed 2011, February 22.
8. Hanefeld M, Brunetti P, Schernthaner GH, et al. One year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes care [serial online] 2004 January: 27(1):141-147. Available from: http://care.diabetesjournals.org/content/27/1/141.short. Accessed 2011, February 22.
9. Pfutzner A, Marx n, Lubben G, et al. improvement of cardiovascular risk markers by pioglitazone is independent from glucemic control. J Am Coll [serial online] 2005:45:1925-1931. Available from: http://content.onlinejace.org/cgggi/content/short/45/12/1925. Accessed 2011, February 22.
10. Nishio K, Sakorai M, Kusuyama T, et al. a randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type-2 diabetes. Diabetes care [serial online] 2006 January: 29(1): 101-106. Available from: http://care.diabetesjournals.org/content/29/1/101.full. Accessed 2011, February 22.
11. Raskin P, Rendell M, Riddle MC, et al. a randomized trail of rosiglitazone therapy in patients with inadequately controlled insulin treated type-2 diabetes. Diabetes care [serial online] 2001 July: 24(7): 1226-1232. Available from: http://care.diabetesjournals.org/content/24/7/1226.full. Accessed 2011, February 22.
12. Lebovitz HE, Dole JF, Patwardhan R, et al. rosiglitazone monotherapy is effective inpatients with type-2 diabetes. The journal of clinical endocrinology & metabolism [serial online] 2001: 86(1): 280-288. Available from: http://jcem.endojournals.org/cgi/content/full/jcem;86/1/280. Accessed 2011, February 22.
13. Phillips LS, Gronberger G, Miller E, et al. once and twice-daily dosing with rosiglitazone improves glycemic control in patients with type-2 diabetes. Diabetes care [serial online] 2001 February:24(2): 308-315. Available from: http://care.diabetesjournals.org/content/24/2/308.full. Accessed 2011, February 22.
14. Fonseca V, Rosenstock J, Patwardhan R, et al. effect of metformin and rosiglitazone combination therapy in patients with type-2 diabetes mellitus. JAMA [serial online] 2000 April: 283(13): 1695. Available from: http://jama.ama-assn.org/content/283/13/1695.long. Accesssed 2011, February 22.
15. Albert KG, Eckel RH, Grundy SM, et al. harmonizing the metabolic syndrome. Circulation [serial online] 2009: 120: 1640-1645. Available from: http://circ.ahajournals.org/cgi/content/full/120/16/1640. Accessed 2011, March 19.
16. Grundy SM, Clecman JI, Daniels SR, et al. diagnosis and management of the metabolic syndrome: An American heart association/National heart, lung and blood institute scientific statement. Circulation [serial online] 2005: 112: 2735-2752. Available from: http;//circ.ahajournals.org/cgi/reprint/CIRCULATION AHA .105. 169404v1. Accessed 2011, March 19.
17. Tripathi KP. Essentials of medical pharmacology. 6th ed. New Delhi: Jaypee brothers’ medical publishers (p) Ltd; 2008. P. 254-274.
18. Buse JB, polonsky KS, Burant CR. Type 2 diabetes mellitus. In: Kronenberg HM, Melmed S, Polonsky KS, et al editors. Williams’s textbook of endocrinology [online] 11th ed.Philadelphia: Saunders Elsevier; 2008. Available from: http://www.mdconsult.com/books/page.do. Accessed 2011, March 20.
19. Chiquette E, Ramirez G, Deofronzo R, et al. A meta-analysis-comparing the effect of thiazolidinediones on cardiovascular risk factor. Archives of Internal Medicine [serial online] 2004 October: 164 (19): 2097-2104. Available
from: http://archinte.ama-assn.org/cgi/content/full/164/19/2097. Accessed 2011, February 15.
20. Wilcox R, Kupfer S, Erdmann E, et al. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type-2 diabetes: Results from prospective pioglitazone clinical trial in macrovascular event (PROactive 10). American Heart Journal [seria online] 2008 April: 155(4). Available from: http://www.mdconsult.com/das/article/body/237779776-9/jorg. Accessed 2011, March 22.
21. Home PD, Pocock SJ, Nielsen HB, et al. Rosiglitazone evaluated for cardiovascular outcomes-An interim analysis. NEJM [serial online] 2007: 317: 28-38. Available from: http://www.nejm.org/doi/full/10.1056/NEJM00073394/t=abstract. Accessed 2011, March 22.
22. Loke YK. Comparative cardiovascular effects of thiazolidinediones: Systematic review and mata-analysis of observational studies. BMJ [serial online] 2011: 342: d1309. Available from: http://www.bmj.com/content/342/bmj.d1309.full. Accessed 2011, March 21.
